

**Glypican 3 (GPC3) Antibody (N-term)**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP6337a**

**Specification**

**Glypican 3 (GPC3) Antibody (N-term) - Product Information**

Application	<b>WB, IHC-P,E</b>
Primary Accession	<a href="#">P51654</a>
Reactivity	<b>Human, Mouse</b>
Host	<b>Rabbit</b>
Clonality	<b>Polyclonal</b>
Isotype	<b>Rabbit Ig</b>
Antigen Region	<b>21-50</b>

**Glypican 3 (GPC3) Antibody (N-term) - Additional Information**

**Gene ID 2719**

**Other Names**

Glypican-3, GTR2-2, Intestinal protein OCI-5, MXR7, Secreted glypican-3, GPC3, OCI5

**Target/Specificity**

This Glypican 3 (GPC3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 21-50 amino acids from the N-terminal region of human Glypican 3 (GPC3).

**Dilution**

WB~~1:1000  
IHC-P~~1:50~100

**Format**


Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

**Storage**


Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

Glypican 3 (GPC3) Antibody (N-term) is for research use only and not for use in



Anti-GPC3 Antibody (C35) at 1:2000 dilution + Jurkat whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 66 kDa  
Blocking/Dilution buffer: 5% NFDM/TBST.



Anti-GPC3 Antibody (C35) at 1:2000 dilution + HepG2 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 65 kDa

diagnostic or therapeutic procedures.

#### Glypican 3 (GPC3) Antibody (N-term) - Protein Information

**Name** GPC3


**Synonyms** OCI5

#### Function


Cell surface proteoglycan that bears heparan sulfate (PubMed:<a href="http://www.uniprot.org/citations/14610063" target="\_blank">14610063</a>). Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins (By similarity). Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation (By similarity). Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands (PubMed:<a href="http://www.uniprot.org/citations/16227623" target="\_blank">16227623</a>, PubMed:<a href="http://www.uniprot.org/citations/24496449" target="\_blank">24496449</a>). Positively regulates the non- canonical Wnt signaling pathway (By similarity). Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression (By similarity). Inhibits the dipeptidyl peptidase activity of DPP4 (PubMed:<a href="http://www.uniprot.org/citations/17549790" target="\_blank">17549790</a>). Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4 (By similarity). Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis (By similarity). Required for coronary vascular development (By similarity). Plays a role in regulating cell movements during gastrulation (By similarity).

#### Cellular Location

Blocking/Dilution buffer: 5% NFDM/TBST.



GPC3 Antibody(C35) (cat# AP6337a) western blot analysis in mouse stomach tissue lysates (35ug/lane).This demonstrates the GPC3 antibody detected the GPC3 protein (arrow).



Glypican 3 (GPC3) Antibody (N-term) (Cat. #AP6337a)immunohistochemistry analysis in formalin fixed and paraffin embedded human liver tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of Glypican 3 (GPC3) Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.

#### Glypican 3 (GPC3) Antibody (N-term) - Background

GPC3 is a cell surface proteoglycan that bears heparan sulfate. This protein may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. Members of the

Cell membrane; Lipid-anchor, GPI-anchor  
{ECO:0000250|UniProtKB:P13265};  
Extracellular side  
{ECO:0000250|UniProtKB:P13265}

**Tissue Location**

Highly expressed in lung, liver and kidney.

**Glypican 3 (GPC3) Antibody (N-term) -  
Protocols**

Provided below are standard protocols that you  
may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**Glypican 3 (GPC3) Antibody (N-term) - Citations**

- [Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer.](#)

glypican-related integral membrane  
proteoglycan family contain a core protein  
anchored to the cytoplasmic membrane via a  
glycosyl phosphatidylinositol (GPI) linkage.  
These proteins may play a role in the control of  
cell division, growth regulation, and tumor  
predisposition. Deletion mutations in GPC3 are  
the cause of Simpson-Golabi-Behmel syndrome  
(SGBS), also known as Simpson dysmorphism  
syndrome (SDYS). SGBS is a condition  
characterized by pre- and postnatal  
overgrowth (gigantism) with visceral and  
skeletal anomalies.

**Glypican 3 (GPC3) Antibody (N-term) -  
References**

Nakatsura, T., et al., Clin. Cancer Res.  
10(19):6612-6621 (2004). Boily, G., et al., Br. J.  
Cancer 90(8):1606-1611 (2004). Wichert, A., et  
al., Oncogene 23(4):945-955 (2004).  
Midorikawa, Y., et al., Int. J. Cancer  
103(4):455-465 (2003). Sung, Y.K., et al.,  
Cancer Sci. 94(3):259-262 (2003).